LONDON – Mesoblast Ltd. is preparing to discuss plans for Phase III development with regulators and weighing the partnering strategy after reporting positive Phase II results for its Neofuse cell therapy for treating degenerative disc disease by lumber spinal fusion. Read More

LONDON – An unexpected finding about how tadpoles control the regeneration of a tail that has been lost will trigger new research into healing and regeneration of wounds and tissues in humans. Read More

The plan to introduce value-based pricing of drugs in the UK in January 2014 lacks clarity, with the arrangements for the new system still not agreed on and companies that will have to work with the new arrangements uncertain about what they will mean in practice. Read More

With an established reputation for its generic drugs, Mumbai, India-based Lupin Ltd. has expanded into biosimilars in its quest to become a global biopharma powerhouse. But like the foggy view from the 32nd-floor penthouse location of the Asia track at the J.P. Morgan Healthcare Conference last week, the firm's chief financial officer provided limited insight into the company's biosimilars strategy despite audience questions. Read More

• MorphoSys AG, of Martinsried, Germany, said it completed the sale of research and diagnostic antibody division AbD Serotec to Bio-Rad Laboratories Inc., of Hercules, Calif., for about $70 million in cash. Read More